Lymphocyte activation gene 3 (LAG-3) is a recently discovered cell surface molecule which shows promise as a biomarker in cancer patients. Paolo Ascierto, MD from the National Tumour Institute Fondazione G. Pascale, Naples, Italy speaks to us from the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain about the future of LAG-3 in cancer treatments, and tells us the benefits of an improved understanding of tumor microenvironments.

свернуть